• October 26, 2010
  • North America

NeurAxon’s NXN-188 Named One of 10 Most Promising Neuroscience Projects by WindhoverNeurAxon to Present at Windhover's Therapeutic Area Partnerships Conference on November 3

WALTHAM, MA – October 26, 2010 – NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that NXN-188, a novel oral selective nitric oxide synthase inhibitor and 5HT agonist in development for acute migraine, has been selected as one of the Top 10 most promising neuroscience projects currently available for strategic partnering. Selection was determined by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries.

As a selected company, NeurAxon has been invited to participate in Windhover’s Therapeutic Area Partnerships conference taking place November 2-4, 2010, in Boston, MA. Lawrence Bloch, M.D., J.D., the Company’s Chief Executive Officer, will present an overview of NXN-188 development progress on Wednesday, November 3, 2010 beginning at 1:00pm Eastern Time in the Essex Center Room at the Westin Copley Place.

About Windhover
Windhover Information Inc, an Elsevier company, has provided analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO: The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and webinars. For more on the company’s products and services, please see http://www.windhover.com.

About NXN-188
NXN-188 is a first-in-class small molecule that is being developed for the treatment of acute migraine and which incorporates both first-in-class nNOS inhibition and 5-HT agonism (the mechanism of action of triptans, the current standard of care in migraine therapy). NOS is a validated target for migraine therapy as nitric oxide induces migraines in migraineurs, while the inhibition of NOS has been demonstrated to relieve migraine pain.

About NeurAxon Inc.
NeurAxon, Inc. (www.neuraxon.com) discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.

Chris Erdman
MacDougall Biomedical Communications